PureTech
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, PureTech sits in the upper quartile of US sponsors by registered trial count (#2,085 of 15,742 sponsors by registered trial count).
PureTech: 6 sponsored US clinical trials, 1 recruiting.
PureTech sponsors 6 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 2 completed. 0 of these trials are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is AML, Adult Recurrent, with 1 trials.
Upper-quartile sponsor footprint
PureTech sits in the upper quartile of the sponsor corpus (#2,085 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
6 total, page 1 of 1
A Phase 1 Study With LYT-200 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML), or With Relapsed/Refractory, High-risk Myelodysplastic Syndrome (MDS)
NCT05829226
LYT-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
NCT05321420
PK of Deupirfenidone Versus Pirfenidone in Older Healthy Subjects
NCT07456800
LYT-200 Alone and in Combination With Chemotherapy or Tislelizumab in Patients With Locally Advanced or Metastatic Solid Tumors
NCT04666688
LYT-100 in Post-acute COVID-19 Respiratory Disease
NCT04652518
LYT-100 in Patients With BCRL
NCT04243837
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 3 |
| Phase 2 | 3 |
Therapeutic Areas
What is open in the PureTech pipeline
1 recruiting of 6 indexed (17% open); 2 completed (33%).
Phase mix: 0 late (III/IV) vs 6 early (I/II) (early-phase heavy).
Top condition: AML, Adult Recurrent (1 trial), 8 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
PureTech: open-pipeline peers nationwide
Peers matched on 6 registered trials and 17% open enrollment, not the therapeutic-area sidebar.
PureTech sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 6 trials (± recruiting share)
- 23andMe · 6 trials · 0% recruiting
- Aardvark Therapeutics · 6 trials · 0% recruiting
- Abbisko Therapeutics Co · 6 trials · 67% recruiting
- AbGenomics B.V Taiwan Branch · 6 trials · 0% recruiting
Sponsors near 17% open enrollment (± trial volume)
- Adagene · 17% recruiting · 6 trials
- Agendia · 17% recruiting · 6 trials
- Akamis Bio · 17% recruiting · 6 trials
- Angiodynamics · 17% recruiting · 12 trials
Related
What to do with this PureTech page
6 registered trials is a research-attention snapshot, not an endorsement of PureTech or any single study.
- 1 of PureTech's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- AML, Adult Recurrent is the condition PureTech studies most, compare against other sponsors active in the same condition before evaluating a specific study. See AML, Adult Recurrent trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
PureTech pipeline card: 6 registered trials from official public datasets.Report a data error.